Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, Xavier; Hauser, Stephen L.; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Comi, Giancarlo; de Seze, Jérôme; Giovannoni, Gavin; Hartung, Hans-Peter; Hemmer, Bernhard; Lublin, Fred; Rammohan, Kottil W.; Selmaj, Krzysztof; Traboulsee, Anthony; Sauter, Annette; Masterman, Donna; Fontoura, Paulo; Belachew, Shibeshih; Garren, Hideki; Mairon, Nicole; Chin, Peter; Wolinsky, Jerry S.; Elovaara, Irina; Sumelahti, Marja-Liisa; for the ORATORIO Clinical Investigators (2017)
Montalban, Xavier
Hauser, Stephen L.
Kappos, Ludwig
Arnold, Douglas L.
Bar-Or, Amit
Comi, Giancarlo
de Seze, Jérôme
Giovannoni, Gavin
Hartung, Hans-Peter
Hemmer, Bernhard
Lublin, Fred
Rammohan, Kottil W.
Selmaj, Krzysztof
Traboulsee, Anthony
Sauter, Annette
Masterman, Donna
Fontoura, Paulo
Belachew, Shibeshih
Garren, Hideki
Mairon, Nicole
Chin, Peter
Wolinsky, Jerry S.
Elovaara, Irina
Sumelahti, Marja-Liisa
for the ORATORIO Clinical Investigators
2017
New England Journal of Medicine 376 3
209-220
Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.